利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.018 秒)

    Amide derivative
    1.
    发明授权
    Amide derivative 有权
    酰胺衍生物

    公开(公告)号：US07494997B2

    公开(公告)日：2009-02-24

    申请号：US10519722

    申请日：2003-06-27

    申请人： Tetsuo Asaki ,  Taisuke Hamamoto ,  Yukiteru Sugiyama

    发明人： Tetsuo Asaki ,  Taisuke Hamamoto ,  Yukiteru Sugiyama

    IPC分类号： C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  A61K31/506 ,  A61K31/53 ,  A61P35/00

    CPC分类号： C07D239/42 ,  A61K31/505 ,  A61K31/506 ,  C07D401/04

    摘要： The present invention provides an amide derivative represented by the following general formula (1): wherein R1 represents a saturated cyclic amino group, R2 represents alkyl, halogen or haloalkyl, R3 represents hydrogen or halogen, Het 2 represents pyridyl or pyrimidinyl, and Het 1 represents a group of the formula [6], or a salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.

    摘要翻译： 本发明提供由以下通式（1）表示的酰胺衍生物：其中R1表示饱和环状氨基，R2表示烷基，卤素或卤代烷基，R3表示氢或卤素，Het2表示吡啶基或嘧啶基，Het1 表示式[6]的基团，或其盐，以及包含该基团的药物组合物作为活性成分。 本发明的化合物可用作BCR-ABL酪氨酸激酶抑制剂。

    Amide derivative
    2.
    发明申请
    Amide derivative 有权
    酰胺衍生物

    公开(公告)号：US20060014742A1

    公开(公告)日：2006-01-19

    申请号：US10519722

    申请日：2003-06-27

    申请人： Tetsuo Asaki ,  Taisuke Hamamoto ,  Yukiteru Sugiyama

    发明人： Tetsuo Asaki ,  Taisuke Hamamoto ,  Yukiteru Sugiyama

    IPC分类号： A61K31/53 ,  A61K31/501 ,  A61K31/506 ,  A61K31/497 ,  A61K31/444 ,  C07D403/02 ,  C07D401/02

    CPC分类号： C07D239/42 ,  A61K31/505 ,  A61K31/506 ,  C07D401/04

    摘要： The present invention provides an amide derivative represented by the following general formula (1): wherein R1 represents a saturated cyclic amino group, R2 represents alkyl, halogen or haloalkyl, R3 represents hydrogen or halogen, Het 2 represents pyridyl or pyrimidinyl, and Het 1 represents a group of the formula [6], or a salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.

    摘要翻译： 本发明提供由以下通式（1）表示的酰胺衍生物：其中R 1表示饱和环状氨基，R 2表示烷基，卤素或卤代烷基， R 3表示氢或卤素，Het 2表示吡啶基或嘧啶基，Het 1表示式[6]的基团或其盐，以及包含其作为活性成分的药物组合物 。 本发明的化合物可用作BCR-ABL酪氨酸激酶抑制剂。

    Amide Derivative and Medicine
    3.
    发明申请
    Amide Derivative and Medicine 有权
    酰胺衍生物和医学

    公开(公告)号：US20080293940A1

    公开(公告)日：2008-11-27

    申请号：US10584829

    申请日：2004-12-27

    申请人： Tetsuo Asaki ,  Yukiteru Sugiyama ,  Jun Segawa

    发明人： Tetsuo Asaki ,  Yukiteru Sugiyama ,  Jun Segawa

    IPC分类号： C07D403/14 ,  C07D239/24 ,  C07D295/00

    CPC分类号： C07D239/42 ,  A61K9/2054 ,  C07D213/74 ,  C07D401/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D417/04

    摘要： The present invention is directed to an amide derivative having excellent BCR-ABL tyrosine kinase inhibitory activity, or a salt thereof.The present invention provides an amide derivative represented by the following general formula (1):[Chemical 23] (wherein R1 represents —CH2—R11, etc.; R2 represents alkyl, halogen, haloalkyl, etc.; R3 represents hydrogen, etc.; Het1 represents a group of the formula [6] as above, etc.; and Het2 represents pyrimidinyl, etc.), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient.The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.

    摘要翻译： 本发明涉及具有优异的BCR-ABL酪氨酸激酶抑制活性的酰胺衍生物或其盐。 本发明提供由以下通式（1）表示的酰胺衍生物：[化学式23]（式中，R 1表示-CH 2 -R 11等; R 2表示烷基，卤素，卤代烷基等; R 3表示氢等。 ; Het1表示上述式[6]的基团等; Het2表示嘧啶基等）或其药学上可接受的盐，以及包含其作为活性成分的药物组合物。 本发明的化合物可用作BCR-ABL酪氨酸激酶抑制剂。

    Amide derivative and medicine
    4.
    发明授权
    Amide derivative and medicine 有权
    酰胺衍生物和药物

    公开(公告)号：US07728131B2

    公开(公告)日：2010-06-01

    申请号：US10584829

    申请日：2004-12-27

    申请人： Tetsuo Asaki ,  Yukiteru Sugiyama ,  Jun Segawa

    发明人： Tetsuo Asaki ,  Yukiteru Sugiyama ,  Jun Segawa

    IPC分类号： C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  A61K31/53 ,  A61K31/506

    CPC分类号： C07D239/42 ,  A61K9/2054 ,  C07D213/74 ,  C07D401/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D417/04

    摘要： The present invention is directed to an amide derivative having excellent BCR-ABL tyrosine kinase inhibitory activity, or a salt thereof.The present invention provides an amide derivative represented by the following general formula (1):[Chemical 23] (wherein R1 represents —CH2—R11, etc.; R2 represents alkyl, halogen, haloalkyl, etc.; R3 represents hydrogen, etc.; Het1 represents a group of the formula [6] as above, etc.; and Het2 represents pyrimidinyl, etc.), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.

    摘要翻译： 本发明涉及具有优异的BCR-ABL酪氨酸激酶抑制活性的酰胺衍生物或其盐。 本发明提供由以下通式（1）表示的酰胺衍生物：[化学式23]（式中，R 1表示-CH 2 -R 11等; R 2表示烷基，卤素，卤代烷基等; R 3表示氢等。 ; Het1表示上述式[6]的基团等; Het2表示嘧啶基等）或其药学上可接受的盐，以及包含其作为活性成分的药物组合物。 本发明的化合物可用作BCR-ABL酪氨酸激酶抑制剂。

    Production process of purified green tea extract
    5.
    发明申请
    Production process of purified green tea extract 有权
    纯化绿茶提取物的生产工艺

    公开(公告)号：US20060263454A1

    公开(公告)日：2006-11-23

    申请号：US11434069

    申请日：2006-05-16

    申请人： Yukiteru Sugiyama ,  Hideaki Ueoka

    发明人： Yukiteru Sugiyama ,  Hideaki Ueoka

    IPC分类号： A61K36/82 ,  A23F3/00

    CPC分类号： A23F3/20 ,  A23F3/163

    摘要： A process for producing a purified product of green tea extract, which includes subjecting an aqueous solution of green tea extract to solid-liquid separation by filtration and/or centrifugal separation to obtain another aqueous solution of green tea extract, said another aqueous solution having a turbidity of from 0.2 to 2.0 as measured with a concentration of non-polymer catechins in it adjusted to 1 wt %, and then allowing the another aqueous solution of green tea extract to pass through a polymer membrane having a membrane pore size of from 0.05 to 0.8 μm such that the turbidity of the another aqueous solution of green tea extract is reduced to lower than 0.2 as measured with a concentration of non-polymer catechins in it adjusted to 1 wt %.

    摘要翻译： 一种生产绿茶提取物的纯化产物的方法，其包括通过过滤和/或离心分离使绿茶提取物的水溶液进行固液分离，得到另一种绿茶提取物水溶液，所述另一种水溶液具有 将浓度为1重量％的非聚合物儿茶素类的浓度测定为0.2〜2.0的浊度，然后使另一种绿茶提取物水溶液通过膜孔径为0.05〜0.05的聚合物膜 0.8微米，使得绿茶提取物的另一个水溶液的浊度降低到低于0.2，其中非聚合型儿茶素类的浓度被调节到1重量％。

    Process for production of purified chlorogenic acid-containing pharmaceutical preparation
    8.
    发明授权
    Process for production of purified chlorogenic acid-containing pharmaceutical preparation 有权
    纯化含绿原酸的药物制剂的生产工艺

    公开(公告)号：US08778423B2

    公开(公告)日：2014-07-15

    申请号：US13808750

    申请日：2011-07-06

    申请人： Yukiteru Sugiyama ,  Kenji Yamawaki ,  Yuko Kubo

    发明人： Yukiteru Sugiyama ,  Kenji Yamawaki ,  Yuko Kubo

    IPC分类号： A61K36/74 ,  A61K36/185

    CPC分类号： C07C67/56 ,  A23L2/52 ,  A23L33/105 ,  A23V2002/00 ,  A23V2200/00 ,  C07C69/732 ,  C07C2601/14 ,  A23V2200/02 ,  A23V2200/326 ,  A23V2250/2108 ,  A23V2250/2132

    摘要： Provided is a process for producing a purified chlorogenic acid-containing preparation, which is useful for the production of a chlorogenic acid-containing beverage with reduced developability of turbidity even in an acidic range.The process for producing a purified chlorogenic acid-containing preparation according to the present invention includes a first step of dispersing or dissolving a chlorogenic acid-containing composition as a starting material in the presence of acid clay or activated clay in a mixed solvent of an organic solvent and water, a second step of removing a deposit from a dispersion or solution obtained by the first step, a third step of adjusting a concentration of chlorogenic acids and pH in a solution, which has been obtained by the second step, to from 1.5 to 10 mass % and from 2 to 4, respectively, and a fourth step of separating the deposit formed in a concentration-adjusted solution obtained by the third step.

    摘要翻译： 本发明提供一种生产纯化的含绿原酸的制剂的方法，其可用于生产即使在酸性范围内具有降低的浊度显示性的含绿原酸的饮料。 根据本发明的含有纯化绿原酸的制剂的制备方法包括在酸性粘土或活性白土存在下，在有机物的混合溶剂中分散或溶解含有绿原酸的组合物作为原料的第一步骤 溶剂和水的第二步骤，从通过第一步获得的分散体或溶液中除去沉积物的第二步骤，将通过第二步获得的溶液中的绿原酸浓度和pH值调节至1.5的第三步骤 分别为10质量％和2〜4，第四步是分离通过第三步获得的浓度调节溶液中形成的沉积物。

    PROCESS FOR PRODUCTION OF PURIFIED CHLOROGENIC ACID-CONTAINING PHARMACEUTICAL PREPARATION
    9.
    发明申请
    PROCESS FOR PRODUCTION OF PURIFIED CHLOROGENIC ACID-CONTAINING PHARMACEUTICAL PREPARATION 有权
    生产纯化含氯酸的药物制备方法

    公开(公告)号：US20130131165A1

    公开(公告)日：2013-05-23

    申请号：US13808750

    申请日：2011-07-06

    申请人： Yukiteru Sugiyama ,  Kenji Yamawaki ,  Yuko Kubo

    发明人： Yukiteru Sugiyama ,  Kenji Yamawaki ,  Yuko Kubo

    IPC分类号： C07C67/56 ,  C07C69/732

    CPC分类号： C07C67/56 ,  A23L2/52 ,  A23L33/105 ,  A23V2002/00 ,  A23V2200/00 ,  C07C69/732 ,  C07C2601/14 ,  A23V2200/02 ,  A23V2200/326 ,  A23V2250/2108 ,  A23V2250/2132

    摘要： Provided is a process for producing a purified chlorogenic acid-containing preparation, which is useful for the production of a chlorogenic acid-containing beverage with reduced developability of turbidity even in an acidic range.The process for producing a purified chlorogenic acid-containing preparation according to the present invention includes a first step of dispersing or dissolving a chlorogenic acid-containing composition as a starting material in the presence of acid clay or activated clay in a mixed solvent of an organic solvent and water, a second step of removing a deposit from a dispersion or solution obtained by the first step, a third step of adjusting a concentration of chlorogenic acids and pH in a solution, which has been obtained by the second step, to from 1.5 to 10 mass % and from 2 to 4, respectively, and a fourth step of separating the deposit formed in a concentration-adjusted solution obtained by the third step.

    摘要翻译： 本发明提供一种生产纯化的含绿原酸的制剂的方法，其可用于生产即使在酸性范围内具有降低的浊度显示性的含绿原酸的饮料。 根据本发明的含有纯化绿原酸的制剂的制备方法包括在酸性粘土或活性白土存在下，在有机物的混合溶剂中分散或溶解含有绿原酸的组合物作为原料的第一步骤 溶剂和水的第二步骤，从通过第一步获得的分散体或溶液中除去沉积物的第二步骤，将通过第二步获得的溶液中的绿原酸浓度和pH值调节至1.5的第三步骤 分别为10质量％和2〜4，第四步是分离通过第三步获得的浓度调节溶液中形成的沉积物。